# Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

> **NCT04902443** · PHASE1 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 58 (estimated)

## Conditions studied

- Viral Associated Malignancies
- Kaposi Sarcoma
- EBV/KSHV-associated Lymphomas

## Interventions

- **DRUG:** Pomalidomide
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04902443
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-10
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04902443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04902443, "Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04902443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*